[ad_1]
The committee overseeing the implementation of the study with the active ingredient RLF-100 has given the green light to continue the corona development project. Relief Therapeutics announced Thursday.
The data monitoring committee reviewed data from 102 randomly selected patients followed for at least 28 days and concluded that the study with the Geneva-based company’s potential drug has a chance for success. The decision of the seven scientists on the committee was unanimous. The relief therefore survived even the second provisional analysis.
The first with data from thirty patients had already shown a positive trend in the data. Otherwise the commission would have asked for the study to be suspended. Rescue stocks initially gained more than 40% on Thursday, after noon there was a price increase of around a quarter from the previous day’s close.
Please login to read this article in full.
.
[ad_2]
Source link
